Mayo Clinic Proceedings Home

Peripheral Artery Disease: Current Insight Into the Disease and Its Diagnosis and Management

  • Jeffrey W. Olin
    Address correspondence to Jeffery W. Olin, DO, Director, Vascular Medicine, Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY 10029. Individual reprints of this article and a bound reprint of the entire Symposium on Cardiovascular Diseases will be available for purchase from our Web site
    Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY
    Search for articles by this author
  • Brett A. Sealove
    Zena and Michael A. Wiener Cardiovascular Institute and Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY
    Search for articles by this author
      Peripheral artery disease (PAD), which comprises atherosclerosis of the abdominal aorta, iliac, and lower-extremity arteries, is underdiagnosed, undertreated, and poorly understood by the medical community. Patients with PAD may experience a multitude of problems, such as claudication, ischemic rest pain, ischemic ulcerations, repeated hospitalizations, revascularizations, and limb loss. This may lead to a poor quality of life and a high rate of depression. From the standpoint of the limb, the prognosis of patients with PAD is favorable in that the claudication remains stable in 70% to 80% of patients over a 10-year period. However, the rate of myocardial infarction, stroke, and cardiovascular death in patients with both symptomatic and asymptomatic PAD is markedly increased. The ankle brachial index is an excellent screening test for the presence of PAD. Imaging studies (duplex ultrasonography, computed tomographic angiography, magnetic resonance angiography, catheter-based angiography) may provide additional anatomic information if revascularization is planned. The goals of therapy are to improve symptoms and thus quality of life and to decrease the cardiovascular event rate (myocardial infarction, stroke, cardiovascular death). The former is accomplished by establishing a supervised exercise program and administering cilostazol or performing a revascularization procedure if medical therapy is ineffective. A comprehensive program of cardiovascular risk modification (discontinuation of tobacco use and control of lipids, blood pressure, and diabetes) will help to prevent the latter.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hirsch AT
        • Criqui MH
        • Treat-Jacobson D
        • et al.
        Peripheral arterial disease detection, awareness, and treatment in primary care.
        JAMA. 2001; 286: 1317-1324
        • McDermott MM
        • Kerwin DR
        • Liu K
        • et al.
        Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice*.
        J Gen Intern Med. 2001; 16: 384-390
        • McDermott MM
        • Mehta S
        • Ahn H
        • Greenland P
        Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease.
        J Gen Intern Med. 1997; 12: 209-215
        • Hirsch AT
        • Haskal ZJ
        • Hertzer NR
        • et al.
        ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.
        Circulation. 2006; 113: e463-e654
        • McDermott MM
        • Hahn EA
        • Greenland P
        • et al.
        Atherosclerotic risk factor reduction in peripheral arterial disease: results of a national physician survey.
        J Gen Intern Med. 2002; 17: 895-904
        • McDermott MM
        • Greenland P
        • Guralnik JM
        • et al.
        Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease.
        J Gen Intern Med. 2003; 18: 461-467
        • Regensteiner JG
        • Hiatt WR
        • Coll JR
        • et al.
        The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program.
        Vasc Med. 2008; 13: 15-24
        • McDermott MM
        • Guralnik JM
        • Ferrucci L
        • et al.
        Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication.
        Circulation. 2008; 117: 2484-2491
        • Resnick HE
        • Lindsay RS
        • McDermott MM
        • et al.
        Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study.
        Circulation. 2004; 109: 733-739
        • Criqui MH
        • Langer RD
        • Fronek A
        • et al.
        Mortality over a period of 10 years in patients with peripheral arterial disease.
        N Engl J Med. 1992; 326: 381-386
        • Fowkes FG
        • Murray GD
        • Butcher I
        • et al.
        Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.
        JAMA. 2008; 300: 197-208
        • Hiatt WR
        Medical treatment of peripheral arterial disease and claudication.
        N Engl J Med. 2001; 344: 1608-1621
        • Regensteiner JG
        • Hiatt WR
        Current medical therapies for patients with peripheral arterial disease: a critical review.
        Am J Med. 2002; 112: 49-57
        • Newman AB
        • Sutton-Tyrrell K
        • Kuller LH
        Lower-extremity arterial disease in older hypertensive adults.
        Arterioscler Thromb. 1993; 13: 555-562
        • McDermott MM
        • Greenland P
        • Liu K
        • et al.
        The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study.
        Ann Intern Med. 2002; 136: 873-883
        • Meijer WT
        • Hoes AW
        • Rutgers D
        • Bots ML
        • Hofman A
        • Grobbee DE
        Peripheral arterial disease in the elderly: The Rotterdam Study.
        Arterioscler Thromb Vasc Biol. 1998; 18: 185-192
        • Fowkes FG
        • Housley E
        • Cawood EH
        • Macintyre CC
        • Ruckley CV
        • Prescott RJ
        Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population.
        Int J Epidemiol. 1991; 20: 384-392
        • Norgren L
        • Hiatt WR
        • Dormandy JA
        • Nehler MR
        • Harris KA
        • Fowkes FG
        • TASC II Working Group
        Inter-society consensus for the management of peripheral arterial disease (TASC II).
        J Vasc Surg. 2007; 45: S5-S67
        • Criqui MH
        • Fronek A
        • Barrett-Connor E
        • Klauber MR
        • Gabriel S
        • Goodman D
        The prevalence of peripheral arterial disease in a defined population.
        Circulation. 1985; 71: 510-515
        • Kannel WB
        • Shurtleff D
        The Framingham Study: cigarettes and the development of intermittent claudication.
        Geriatrics. 1973; 28: 61-68
        • Powell JT
        • Edwards RJ
        • Worrell PC
        • Franks PJ
        • Greenhalgh RM
        • Poulter NR
        Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study.
        Atherosclerosis. 1997; 129: 41-48
        • Selvin E
        • Hirsch AT
        Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004.
        Atherosclerosis. 2008; 201: 425-433
        • Jonason T
        • Bergstrom R
        Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality.
        Acta Med Scand. 1987; 221: 253-260
        • Selvin E
        • Marinopoulos S
        • Berkenblit G
        • et al.
        Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.
        Ann Intern Med. 2004; 141: 421-431
        • McDermott MM
        • Liu K
        • Criqui MH
        • et al.
        Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis.
        Am J Epidemiol. 2005; 162: 33-41
        • American Diabetes Association
        Peripheral arterial disease in people with diabetes.
        Diabetes Care. 2003; 26: 3333-3341
        • MacGregor AS
        • Price JF
        • Hau CM
        • Lee AJ
        • Carson MN
        • Fowkes FG
        Role of systolic blood pressure and plasma triglycerides in diabetic peripheral arterial disease: The Edinburgh Artery Study.
        Diabetes Care. 1999; 22: 453-458
        • Kannel WB
        • McGee DL
        Update on some epidemiologic features of intermittent claudication: the Framingham Study.
        J Am Geriatr Soc. 1985; 33: 13-18
        • Smith Jr, SC
        • Milani RV
        • Arnett DK
        • et al.
        Atherosclerotic vascular disease conference: writing group II: risk factors.
        Circulation. 2004; 109: 2613-2616
        • Wattanakit K
        • Folsom AR
        • Selvin E
        • et al.
        Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.
        Atherosclerosis. 2005; 180: 389-397
        • Hiatt WR
        • Hoag S
        • Hamman RF
        • San Luis Valley Diabetes Study
        Effect of diagnostic criteria on the prevalence of peripheral arterial disease.
        Circulation. 1995; 91: 1472-1479
      1. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Olin JW
        Hypertension and peripheral arterial disease.
        Vasc Med. 2005; 10: 241-246
        • Newman AB
        • Tyrrell KS
        • Kuller LH
        Mortality over four years in SHEP participants with a low ankle-arm index.
        J Am Geriatr Soc. 1997; 45: 1472-1478
        • Ridker PM
        • Stampfer MJ
        • Rifai N
        Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.
        JAMA. 2001; 285: 2481-2485
        • Bartholomew JR
        • Olin JW
        Pathophysiology of peripheral arterial disease and risk factors for its development.
        Cleve Clin J Med. 2006; 73: S8-S14
        • Fung ET
        • Wilson AM
        • Zhang F
        • et al.
        A biomarker panel for peripheral arterial disease.
        Vasc Med. 2008; 13: 217-224
        • Wilson AM
        • Kimura E
        • Harada RK
        • et al.
        ß2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies.
        Circulation. 2007; 116: 1396-1403
        • McDermott MM
        • Green D
        • Greenland P
        • et al.
        Relation of levels of hemostatic factors and inflammatory markers to the ankle brachial index.
        Am J Cardiol. 2003; 92: 194-199
        • McDermott MM
        • Greenland P
        • Green D
        • et al.
        D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease.
        Circulation. 2003; 107: 3191-3198
        • Albert MA
        • Ridker PM
        The role of C-reactive protein in cardiovascular disease risk.
        Curr Cardiol Rep. 1999; 1: 99-104
        • Dormandy JA
        • Rutherford RB
        • TASC Working Group
        • TransAtlantic Inter-Society Concensus (TASC)
        Management of peripheral arterial disease (PAD).
        J Vasc Surg. 2000; 31: S1-S296
        • Krajewski LP
        • Olin JW
        Atherosclerosis of the aorta and lower-extremity arteries.
        in: Young JR Olin JW Bartholomew JR Peripheral Vascular Diseases. 2nd ed. CV Mosby, Philadelphia, PA1996: 208-233
        • Olin JW
        Evaluation of the peripheral circulation.
        in: Izzo Jr, JL Sica DA Black HR Hypertension Primer. Lippincott Williams &Wilkins, Philadelphia, PA2008: 374-378
        • Pickett CA
        • Jackson JL
        • Hemann BA
        • Atwood JE
        Carotid bruits as a prognostic indicator of cardiovascular death and myocardial infarction: a meta-analysis.
        Lancet. 2008; 371: 1587-1594
        • Hiatt WR
        • Brass EP
        Pathophysiology of intermittent claudication.
        in: Creager MA Dzau VJ Loscalzo J Vascular Medicine, A Companion to Braunwald's Heart Disease. Saunders, Elsevier, Philadelphia, PA2006: 239-247
        • Regensteiner JG
        • Wolfel EE
        • Brass EP
        • et al.
        Chronic changes in skeletal muscle histology and function in peripheral arterial disease.
        Circulation. 1993; 87: 413-421
        • England JD
        • Ferguson MA
        • Hiatt WR
        • Regensteiner JG
        Progression of neuropathy in peripheral arterial disease.
        Muscle Nerve. 1995; 18: 380-387
        • Vogt MT
        • Cauley JA
        • Newman AB
        • Kuller LH
        • Hulley SB
        Decreased ankle/arm blood pressure index and mortality in elderly women.
        JAMA. 1993; 270: 465-469
        • McKenna M
        • Wolfson S
        • Kuller L
        The ratio of ankle and arm arterial pressure as an independent predictor of mortality.
        Atherosclerosis. 1991; 87: 119-128
        • Newman AB
        • Shemanski L
        • Manolio TA
        • Cardiovascular Health Study Group
        • et al.
        Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study.
        Arterioscler Thromb Vasc Biol. 1999; 19: 538-545
        • Criqui MH
        • Coughlin SS
        • Fronek A
        Noninvasively diagnosed peripheral arterial disease as a predictor of mortality: results from a prospective study.
        Circulation. 1985; 72: 768-773
        • Newman AB
        • Siscovick DS
        • Manolio TA
        • Cardiovascular Heart Study (CHS) Collaborative Research Group
        • et al.
        Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study.
        Circulation. 1993; 88: 837-845
        • Zheng ZJ
        • Sharrett AR
        • Chambless LE
        • et al.
        Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study.
        Atherosclerosis. 1997; 131: 115-125
        • Burek KA
        • Sutton-Tyrrell K
        • Brooks MM
        • et al.
        Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI).
        J Am Coll Cardiol. 1999; 34: 716-721
        • Saw J
        • Bhatt DL
        • Moliterno DJ
        • et al.
        The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials.
        J Am Coll Cardiol. 2006; 48: 1567-1572
        • Olin JW
        in: Garcia MJ Noninvasive Cardiovascular Imaging: A Multimodality Approach. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA2010: 252-268
        • Carter SA
        Indirect systolic pressures and pulse waves in arterial occlusive diseases of the lower extremities.
        Circulation. 1968; 37: 624-637
        • Carter SA
        Clinical measurement of systolic pressures in limbs with arterial occlusive disease.
        JAMA. 1969; 207: 1869-1874
        • Jager KA
        • Ricketts HJ
        • Strandness Jr, DE
        Duplex scanning for the evaluation of lower limb arterial disease.
        in: Bernstein EF Noninvasive Diagnostic Techniques in Vascular Disease. CV Mosby, St Louis, MO1985: 619-631
        • Kohler TR
        • Nance DR
        • Cramer MM
        • Vandenburghe N
        • Strandness Jr, DE
        Duplex scanning for diagnosis of aortoiliac and femoropopliteal disease: a prospective study.
        Circulation. 1987; 76: 1074-1080
        • Moneta GL
        • Yeager RA
        • Antonovic R
        • et al.
        Accuracy of lower extremity arterial duplex mapping.
        J Vasc Surg. 1992; 15: 275-283
        • Whelan JF
        • Barry MH
        • Moir JD
        Color flow Doppler ultrasonography: comparison with peripheral arteriography for the investigation of peripheral vascular disease.
        J Clin Ultrasound. 1992; 20: 369-374
        • Olin JW
        • Kaufman JA
        • Bluemke DA
        • et al.
        Atherosclerotic Vascular Disease Conference. American Heart Association, Imaging, Writing Group IV.
        Circulation. 2004; 109: 2626-2633
        • Prince MR
        • Meaney JF
        Expanding role of MR angiography in clinical practice.
        Eur Radiol. 2006; 16: B3-B8
        • Ersoy H
        • Zhang H
        • Prince MR
        Peripheral MR angiography.
        J Cardiovasc Magn Reson. 2006; 8: 517-528
        • Prince MR
        Peripheral vascular MR angiography: the time has come.
        Radiology. 1998; 206: 592-593
        • Prince MR
        • Narasimham DL
        • Stanley JC
        • et al.
        Breath-hold gadolinium-enhanced MR angiography of the abdominal aorta and its major branches.
        Radiology. 1995; 197: 785-792
        • Grist TM
        MRA of the abdominal aorta and lower extremities.
        J Magn Reson Imaging. 2000; 11: 32-43
        • Fleischmann D
        • Hallett RL
        • Rubin GD
        CT angiography of peripheral arterial disease.
        J Vasc Interv Radiol. 2006; 17: 3-26
        • Rubin GD
        • Shiau MC
        • Leung AN
        • Kee ST
        • Logan LJ
        • Sofilos MC
        Aorta and iliac arteries: single versus multiple detector-row helical CT angiography.
        Radiology. 2000; 215: 670-676
        • Rubin GD
        • Schmidt AJ
        • Logan LJ
        • Sofilos MC
        Multi-detector row CT angiography of lower extremity arterial inflow and runoff: initial experience.
        Radiology. 2001; 221: 146-158
        • Sun Z
        Diagnostic accuracy of multislice CT angiography in peripheral arterial disease.
        J Vasc Interv Radiol. 2006; 17: 1915-1921
        • Hobbs SD
        • Wilmink AB
        • Adam DJ
        • Bradbury AW
        Assessment of smoking status in patients with peripheral arterial disease.
        J Vasc Surg. 2005; 41: 451-456
        • Hobbs SD
        • Bradbury AW
        Smoking cessation strategies in patients with peripheral arterial disease: an evidence-based approach.
        Eur J Vasc Endovasc Surg. 2003; 26: 341-347
        • Heart Protection Study Collaborative Group
        MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Amarenco P
        • Bogousslavsky J
        • Callahan III, A
        • et al.
        High-dose atorvastatin after stroke or transient ischemic attack.
        N Engl J Med. 2006; 355: 549-559
      2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994; 344: 1383-1389
        • Ridker PM
        • Danielson E
        • Fonseca FA
        • et al.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • McDermott MM
        • Guralnik JM
        • Greenland P
        • et al.
        Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease.
        Circulation. 2003; 107: 757-761
        • Giri J
        • McDermott MM
        • Greenland P
        • et al.
        Statin use and functional decline in patients with and without peripheral arterial disease.
        J Am Coll Cardiol. 2006; 47: 998-1004
        • Mohler III, ER
        • Hiatt WR
        • Creager MA
        Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
        Circulation. 2003; 108: 1481-1486
        • Mondillo S
        • Ballo P
        • Barbati R
        • et al.
        Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.
        Am J Med. 2003; 114: 359-364
        • Clement DL
        • De Buyzere ML
        • Duprez DA
        Hypertension in peripheral arterial disease.
        Curr Pharm Des. 2004; 10: 3615-3620
        • Lonn E
        • Yusuf S
        • Dzavik V
        • et al.
        Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).
        Circulation. 2001; 103: 919-925
        • Stumpe KO
        Antihypertensive therapy: new strategies beyond blood pressure control.
        J Cardiovasc Pharmacol. 1992; 20: S1-S4
        • Yusuf S
        • Sleight P
        • Pogue J
        • Bosch J
        • Davies R
        • Dagenais G
        • Heart Outcomes Prevention Evaluation Study Investigators
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
        N Engl J Med. 2000; 342: 145-153
        • Fox KM
        Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
        Lancet. 2003; 362: 782-788
        • Radack K
        • Deck C
        Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials.
        Arch Intern Med. 1991; 151: 1769-1776
        • Antithrombotic Trialist Collaboration
        Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Sobel M
        • Verhaeghe R
        Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
        Chest. 2008; 133: 815S-843S
        • Berger JS
        • Krantz MJ
        • Kittelson JM
        • Hiatt WR
        Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
        JAMA. 2009; 301: 1909-1919
        • Fowkes FG
        • Price JF
        • Stewart MC
        • et al.
        Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.
        JAMA. 2010; 303: 841-848
        • Norgren L
        • Hiatt WR
        • Dormandy JA
        • et al.
        Inter-society consensus for the management of peripheral arterial disease (TASC II).
        Eur J Vasc Endovasc Surg. 2007; 33: S1-S75
        • Belch J
        • MacCuish A
        • Campbell I
        • et al.
        The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.
        BMJ. 2008; 337: a1840
        • Hiatt WR
        • Krantz MJ
        Masterclass series in peripheral arterial disease: antiplatelet therapy for peripheral arterial disease and claudication.
        Vasc Med. 2006; 11: 55-60
        • Wiviott SD
        • Braunwald E
        • McCabe CH
        • et al.
        Prasugrel versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2007; 357: 2001-2015
        • CAPRIE Steering Committee
        A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Yusuf S
        • Zhao F
        • Mehta SR
        • Chrolavicius S
        • Tognoni G
        • Fox KK
        Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Bhatt DL
        • Fox KA
        • Hacke W
        • et al.
        Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
        N Engl J Med. 2006; 354: 1706-1717
        • Bhatt DL
        Prasugrel in clinical practice.
        N Engl J Med. 2009; 361: 940-942
        • Becker RC
        • Moliterno DJ
        • Jennings LK
        • et al.
        Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
        Lancet. 2009; 373: 919-928
        • Morrow DA
        • Scirica BM
        • Fox KA
        • et al.
        Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
        Am Heart J. 2009; 158: 335-341
        • Anand S
        • Yusuf S
        • Xie C
        • et al.
        Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
        N Engl J Med. 2007; 357: 217-227
        • White CJ
        • Gray WA
        Endovascular therapies for peripheral arterial disease: an evidence-based review.
        Circulation. 2007; 116: 2203-2215
        • Gray BH
        • Conte MS
        • Dake MD
        • et al.
        Atherosclerotic peripheral vascular disease symposium II: lower-extremity revascularization: state of the art.
        Circulation. 2008; 118: 2864-2872
        • Murphy TP
        • Hirsch AT
        • Cutlip DE
        • et al.
        Claudication: exercise vs endoluminal revascularization (CLEVER) study update.
        J Vasc Surg. 2009; 50: 942-945
        • Bronas UG
        • Hirsch AT
        • Murphy T
        • et al.
        Design of the multicenter standardized supervised exercise training intervention for the claudication: exercise vs endoluminal revascularization (CLEVER) study.
        Vasc Med. 2009; 14: 313-321
        • Murphy TP
        • Hirsch AT
        • Ricotta JJ
        • et al.
        The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methods.
        J Vasc Surg. 2008; 47: 1356-1363
        • Gardner AW
        • Poehlman ET
        Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis.
        JAMA. 1995; 274: 975-980
        • Regensteiner JG
        • Steiner JF
        • Hiatt WR
        Exercise training improves functional status in patients with peripheral arterial disease.
        J Vasc Surg. 1996; 23: 104-115
        • Stewart KJ
        • Hiatt WR
        • Regensteiner JG
        • Hirsch AT
        Exercise training for claudication.
        N Engl J Med. 2002; 347: 1941-1951
        • Regensteiner JG
        • Gardner A
        • Hiatt WR
        Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: status in 1997.
        Vasc Med. 1997; 2: 147-155
        • Leng GC
        • Fowler B
        • Ernst E
        Exercise for intermittent claudication.
        Cochrane Database Syst Rev. 2000; (CD000990.)
        • McDermott MM
        • Liu K
        • Ferrucci L
        • et al.
        Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more.
        Ann Intern Med. 2006; 144: 10-20
        • Bendermacher BL
        • Willigendael EM
        • Teijink JA
        • Prins MH
        Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication.
        Cochrane Database Syst Rev. 2006; (CD005263.)
        • Girolami B
        • Bernardi E
        • Prins MH
        • et al.
        Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis.
        Arch Intern Med. 1999; 159: 337-345
        • Strano A
        • Davi G
        • Avellone G
        • Novo S
        • Pinto A
        Double-blind, cross-over study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs.
        Angiology. 1984; 35: 459-466
        • Rao KM
        • Simel DL
        • Cohen HJ
        • Crawford J
        • Currie MS
        Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication.
        J Lab Clin Med. 1990; 115: 738-744
        • Franzini E
        • Sellak H
        • Babin-Chevaye C
        • Hakim J
        • Pasquier C
        Effects of pentoxifylline on the adherence of polymorphonuclear neutrophils to oxidant-stimulated human endothelial cells: involvement of cyclic AMP.
        J Cardiovasc Pharmacol. 1995; 25: S92-S95
        • Dawson DL
        • Zheng Q
        • Worthy SA
        • Charles B
        • Bradley Jr, DV
        Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
        Angiology. 2002; 53: 509-520
        • Hood SC
        • Moher D
        • Barber GG
        Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.
        CMAJ. 1996; 155: 1053-1059
        • Porter JM
        • Cutler BS
        • Lee BY
        • et al.
        Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients.
        Am Heart J. 1982; 104: 66-72
        • Gallus AS
        • Gleadow F
        • Dupont P
        • et al.
        Intermittent claudication: a double-blind crossover trial of pentoxifylline.
        Aust N Z J Med. 1985; 15: 402-409
        • De Sanctis MT
        • Cesarone MR
        • Belcaro G
        • et al.
        Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial–walking distance and microcirculation.
        Angiology. 2002; 53: S7-S12
        • Thompson PD
        • Zimet R
        • Forbes WP
        • Zhang P
        Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.
        Am J Cardiol. 2002; 90: 1314-1319
        • Packer M
        • Carver JR
        • Rodeheffer RJ
        • PROMISE Study Research Group
        • et al.
        Effect of oral milrinone on mortality in severe chronic heart failure.
        N Engl J Med. 1991; 325: 1468-1475
        • Dawson DL
        • Cutler BS
        • Hiatt WR
        • et al.
        A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
        Am J Med. 2000; 109: 523-530
        • Hiatt WR
        • Money SR
        • Brass EP
        Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-Term Effects).
        J Vasc Surg. 2008; 47: 330-336
        • Allison MA
        • Hiatt WR
        • Hirsch AT
        • Coll JR
        • Criqui MH
        A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life.
        J Am Coll Cardiol. 2008; 51: 1292-1298
        • Dobesh PP
        • Stacy ZA
        • Persson EL
        Pharmacologic therapy for intermittent claudication.
        Pharmacotherapy. 2009; 29: 526-553
        • Lehert P
        • Comte S
        • Gamand S
        • Brown TM
        Naftidrofuryl in intermittent claudication: a retrospective analysis.
        J Cardiovasc Pharmacol. 1994; 23: S48-S52
        • Lehert P
        • Riphagen FE
        • Gamand S
        The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
        J Cardiovasc Pharmacol. 1990; 16: S81-S86
        • Hiatt WR
        • Hirsch AT
        • Cooke JP
        • Olin JW
        • Brater DC
        • Creager MA
        Randomized trial of AT-1015 for treatment of intermittent claudication: a novel 5-hydroxytryptamine antagonist with no evidence of efficacy.
        Vasc Med. 2004;Feb; 9: 18-25
        • Sneider EB
        • Nowicki PT
        • Messina LM
        Regenerative medicine in the treatment of peripheral arterial disease.
        J Cell Biochem. 2009; 108: 753-761
        • White C
        Clinical practice: intermittent claudication.
        N Engl J Med. 2007; 356: 1241-1250
        • Kalish J
        • Hamdan A
        Management of diabetic foot problems.
        J Vasc Surg. 2010; 51: 476-486

      This activity was designated for 1 AMA PRA Category 1 Credit(s).™

      The contributions to the Symposium on Cardiovascular Diseases are now a CME activity. For CME credit, see the link on our Web site at